| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| DABRAFENIB
| DABRAFENIB | ANTINEOPLASTIC | ORAL | F 95 PERCENT VD 70.3 LITER PPB 99.7 PERCENT Cl 25.7 LITER / HOUR HT 8 HOUR SOLUBILITY PRACTICALLY INSOLUBLE ABOVE PH 4 | BRAF V600E KINASE (IC50=0.65 NANOMOLAR) BRAF V600K (IC50=0.5 NANOMOLAR) BRAF V600D (IC50=1.84 NANOMOLAR) WILD-TYPE BRAF (3.2 NANOMOLAR) CRAF KINASE (5 NANOMOLAR) PDB 5CSW (B-RAF IN COMPLEX WITH DABRAFENIB) LIGAND CODE = P06 (link to the list of PDB complexes) Download experimental 3D coordinates of P06 with added hydrogens | SERINE/THREONINE-PROTEIN KINASE B-RAF INHIBITOR CHEMBL5145 SERINE/THREONINE-PROTEIN KINASE B-RAF P15056 SERINE/THREONINE-PROTEIN KINASE B-RAF HOMO SAPIENS ENZYME KINASE PROTEIN KINASE TKL RAF | EMA | |||
